FDA approves vaccine to block meningitis strain (Update)
Federal health regulators have approved the first vaccine to block a strain of bacteria that has caused sometimes deadly outbreaks of meningitis in college dormitories.
View ArticleUS, German drugmakers team up on cancer medicines
Pfizer said Monday that it will partner with German drug and chemical maker Merck in developing potential cancer drugs in a hot new medication class that harnesses the body's immune system to fight...
View ArticlePfizer closes $635M vaccines purchase from Baxter
Pfizer has completed its $635 million purchase from Baxter International Inc. of two vaccines and part of the factory in Orth, Austria, where they're made.
View ArticleAnalysts: Pfizer's new type of cancer drug may get OK early (Update)
The first in a new class of cancer medicines, Pfizer's Ibrance, appears poised for approval to treat advanced breast cancer within a few months and could quickly become a blockbuster, some analysts...
View ArticlePfizer net down on lower sales, higher research, legal costs
Pfizer Inc.'s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research and legal costs also reduced the bottom line.
View ArticleNew opportunity to treat drug-resistant leukemia discovered
A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center,...
View ArticlePrevnar, Pfizer's pneumonia vaccine, okayed for adults in EU
Pfizer's blockbuster vaccine against pneumonia and other bacterial infections has won another approval, for use in European Union residents aged 18 and older.
View ArticlePfizer stops China vaccine sales as import license expires
Pfizer has stopped selling its Prevnar 7 pneumonia vaccine in China after its import license expired, but the U.S. drugmaker still intends to launch the world's most widely used vaccine, Prevnar 13, in...
View ArticlePfizer buying two meningitis vaccines from Glaxo for $130M
Pfizer will buy two meningitis vaccines from GlaxoSmithKline in a deal that the U.S. drugmaker valued at about $130 million.
View ArticleEU regulators clear Pfizer's purchase of Hospira
European Union regulators on Tuesday approved Pfizer's $15.23 billion purchase of injectable drug and infusion device maker Hospira.
View ArticlePfizer says Hospira purchase will close in early September
Drugmaker Pfizer says it's received the final regulatory approvals for its $15.23 billion purchase of the injectable drug and infusion device maker Hospira, and says the deal will close in early...
View ArticlePfizer beats 3Q expectations, raises 2015 earnings forecast
Pfizer Inc., finally turning the corner after years of generic competition that slashed revenue from the drugmaker's former blockbusters, easily beat Wall Street expectations for the third quarter and...
View ArticlePfizer doubling patient income limit for free drug program
As the furor over soaring U.S. prescription drug prices escalates and outrageous price hikes by several smaller drugmakers give the entire industry a black eye, the biggest U.S.-based drugmaker is...
View ArticlePfizer, Allergan to merge in $160 bn tax-saving deal (Update 3)
US-based Pfizer announced Monday a $160 billion merger with Ireland-based Allergan to create the world's biggest pharmaceutical group and shift to a lower-tax jurisdiction despite government policies...
View Article$160B deal to combine Pfizer and Allergan raises outcry
A $160 billion deal announced Monday to merge Pfizer and Allergan and create the world's biggest drug company renewed the outcry in Washington over "inversions," in which U.S. corporations combine with...
View ArticlePfizer, Allergan CEOs: Tie-up aims for growth, not cost cuts
The heads of drugmakers Pfizer and Allergan said Tuesday that the record $160 billion combination they're planning is meant to produce more medicines and boost revenue, not to just slash jobs and other...
View ArticlePfizer adds $784.6 M charge for Protonix deal to 4Q results
Drugmaker Pfizer Inc. swung to a fourth-quarter financial loss, instead of a modest profit, as a result of a just-announced charge to settle a long-running federal case over reimbursements for its...
View ArticleAdvocates hold NYC protest over price of pneumonia vaccine
Doctors Without Borders protested the price of pneumonia vaccines Wednesday by leading a march through midtown Manhattan and delivering a crib filled with flowers to a pharmaceutical company.
View ArticleMedivation opens door to merger talks with Pfizer, Amgen
US biotech company Medivation has opened the door to being bought by either Pfizer or Amgen, a person familiar with the matter told AFP Tuesday.
View ArticlePfizer says it's blocking use of drugs for lethal injections
Pharmaceutical company Pfizer said Friday it was blocking use of its drugs in lethal injections, which means all federally-approved drugmakers whose medications could be used for executions have now...
View ArticlePfizer buying skin drug maker Anacor for $5.2 billion (Update)
Pfizer is fortifying its key immunology and inflammation drug business, snapping up a small maker of skin disorder treatments for about $5.2 billion, weeks after the U.S. Treasury Department torpedoed...
View ArticlePfizer agrees to note addiction risks in opioid marketing
The city of Chicago and Pfizer announced an agreement Wednesday committing the drugmaker to disclosing the serious risks of addiction in its marketing of prescription opioid painkillers.
View ArticlePfizer beats Street 2Q forecasts despite big drop in profit
Rising sales of Pfizer Inc.'s key new medicines and prospects more drugs will be approved over the next couple years have analysts speculating the biggest U.S. drugmaker won't break up after all.
View ArticlePfizer to launch cheaper version of J&J immune drug Remicade
Drugmaker Pfizer said Monday that it will launch a less-expensive version of rival Johnson & Johnson's blockbuster immune disorder drug, Remicade.
View ArticlePfizer net plunges 38 pct., misses Street 3Q forecasts
Drugmaker Pfizer topped off a difficult third quarter with news that it's scrapping a closely watched experimental cholesterol drug, partly due to expectations insurers would limit access so much that...
View ArticleS.Africa probes 3 drug giants over cancer meds pricing
South Africa's competition commission said Tuesday it had launched investigations into pharmaceutical giants Roche, Pfizer and Aspen for suspected overpricing of cancer drugs.
View ArticleKey drug sales push Pfizer profit up 50 percent
Rising sales of most key drugs, lower one-time charges and reduced manufacturing costs helped drive Pfizer's second-quarter profit up 50 percent.
View ArticlePfizer considers consumer business sale
Pfizer may be done selling ChapStick, Advil, Robitussin and other brands that people can buy without a prescription.
View ArticleViagra goes generic: Pfizer to launch own little white pill
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the...
View ArticleGood news, guys: Viagra prices start to tumble today
(HealthDay)—In news that will delight men who've had difficulties in the bedroom, two generic versions of the erectile dysfunction drug Viagra are scheduled to hit the market Monday.
View Article